Stock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results

Stock Track

Apr 01

Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging agent.

The company reported that results from its Co-PSMA Phase II trial, published in European Urology, showed its copper-64 SAR-bisPSMA PET/CT imaging with next-day scanning detected significantly more cancer sites than the current standard gallium-68 PSMA-11 in men with early biochemical recurrence after prostate removal. The improved detection rate led to changes in planned treatment decisions for 44% of patients, highlighting its potential clinical utility in cases where standard scans often miss the disease.

Clarity positioned the data as supportive of its commercialization plans for SAR-bisPSMA, with the Phase III AMPLIFY trial results still pending. The positive trial outcomes have generated investor optimism regarding the product's future market potential and regulatory pathway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1181835965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181835965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181835965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 12:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181835965","market":"sg","top_or_hot":-1,"title":"Stock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results","media":"Stock Track","content":"<p>Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging agent.</p><p>The company reported that results from its Co-PSMA Phase II trial, published in European Urology, showed its copper-64 SAR-bisPSMA PET/CT imaging with next-day scanning detected significantly more cancer sites than the current standard gallium-68 PSMA-11 in men with early biochemical recurrence after prostate removal. The improved detection rate led to changes in planned treatment decisions for 44% of patients, highlighting its potential clinical utility in cases where standard scans often miss the disease.</p><p>Clarity positioned the data as supportive of its commercialization plans for SAR-bisPSMA, with the Phase III AMPLIFY trial results still pending. The positive trial outcomes have generated investor optimism regarding the product's future market potential and regulatory pathway.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 12:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging agent.</p><p>The company reported that results from its Co-PSMA Phase II trial, published in European Urology, showed its copper-64 SAR-bisPSMA PET/CT imaging with next-day scanning detected significantly more cancer sites than the current standard gallium-68 PSMA-11 in men with early biochemical recurrence after prostate removal. The improved detection rate led to changes in planned treatment decisions for 44% of patients, highlighting its potential clinical utility in cases where standard scans often miss the disease.</p><p>Clarity positioned the data as supportive of its commercialization plans for SAR-bisPSMA, with the Phase III AMPLIFY trial results still pending. The positive trial outcomes have generated investor optimism regarding the product's future market potential and regulatory pathway.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CU6.AU","symbol_name":"CLARITY PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1181835965","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181835965","pubTimestamp":1775018248,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CU6.AU":"CLARITY PHARMACEUTICALS LTD"},"translate_title":"个股追踪|Clarity Pharmaceuticals因前列腺癌成像试验结果阳性盘中大涨5.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CU6.AU":1},"content_text":"Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging agent.The company reported that results from its Co-PSMA Phase II trial, published in European Urology, showed its copper-64 SAR-bisPSMA PET/CT imaging with next-day scanning detected significantly more cancer sites than the current standard gallium-68 PSMA-11 in men with early biochemical recurrence after prostate removal. The improved detection rate led to changes in planned treatment decisions for 44% of patients, highlighting its potential clinical utility in cases where standard scans often miss the disease.Clarity positioned the data as supportive of its commercialization plans for SAR-bisPSMA, with the Phase III AMPLIFY trial results still pending. The positive trial outcomes have generated investor optimism regarding the product's future market potential and regulatory pathway.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}